Alison Mosca Net Worth

The estimated Net Worth of Alison Mosca is at least $19.7 Milhão dollars as of 16 June 2023. Alison Mosca owns over 2,394,375 units of Clene Nanomedicine stock worth over $19,721,704 and over the last 4 years Alison sold CLNN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Alison Mosca CLNN stock SEC Form 4 insiders trading

Alison has made over 4 trades of the Clene Nanomedicine stock since 2021, according to the Form 4 filled with the SEC. Most recently Alison bought 2,394,375 units of CLNN stock worth $1,915,500 on 16 June 2023.

The largest trade Alison's ever made was buying 2,394,375 units of Clene Nanomedicine stock on 16 June 2023 worth over $1,915,500. On average, Alison trades about 154,446 units every 36 days since 2021. As of 16 June 2023 Alison still owns at least 3,238,375 units of Clene Nanomedicine stock.

You can see the complete history of Alison Mosca stock trades at the bottom of the page.

What's Alison Mosca's mailing address?

Alison's mailing address filed with the SEC is 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121.

Insiders trading at Clene Nanomedicine

Over the last 4 years, insiders at Clene Nanomedicine have traded over $1,293,164 worth of Clene Nanomedicine stock and bought 19,236,803 units worth $21,152,263 . The most active insiders traders include David J Matlin, Chidozie Ugwumba, eAlison Mosca. On average, Clene Nanomedicine executives and independent directors trade stock every 26 days with the average trade being worth of $2,786,272. The most recent stock trade was executed by Robert Dee Etherington on 29 July 2024, trading 27,320 units of CLNN stock currently worth $81,960.

What does Clene Nanomedicine do?

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.

Complete history of Alison Mosca stock trades at Clene Nanomedicine

Clene Nanomedicine executives and stock owners

Clene Nanomedicine executives and other stock owners filed with the SEC include:

• Robert Etherington,
  CEO, Pres & Director
• Robert Etherington MBA,
  CEO, Pres & Director
• Mark G. Mortenson,
  Co-Founder & Chief Science Officer
• Dr. Robert Glanzman M.D.,
  Chief Medical Officer
• Dr. Tae Heum Jeong,
  Consultant
• Morgan R. Brown C.P.A., CPA, M.B.A., MBA,
  Chief Financial Officer
• Mary Anne Mcneil,
  Head of HR
• Michael Hotchkin,
  Chief Devel. Officer
• Jerry Miraglia J.D.,
  Gen. Counsel & Corp. Sec.
• Dr. Jeong Ted,
  Chief Financial Officer
• Chidozie Ugwumba,
  10% owner
• Matthew Kiernan,
  
• Arjun Jj Desai,
  
• Vallerie Mc Laughlin,
  
• Shalom Jacobovitz,
  
• Tae Heum Jeong,
  Chief Finance Officer
• Alison Mosca,
  
• David J Matlin,
  
• Mark Mortenson,
  Chief Science Officer
• Robert Glanzman,
  Chief Medical Officer
• Fiona Costello,
  
• Reed N Wilcox,
  
• Robert Dee Etherington,
  Chief Executive Officer
• John Henry Stevens,
  
• Jonathon Gay,
  
• Morgan R Brown,
  Chief Financial Officer
• Resonance Llc General,
  10% owner